More and more individuals are ordering personal genetic test kits to check for ancestral baldness or threads of familial illness. Despite setbacks, Anne Wojcicki’s company 23andMe continues to lead the direct-to-consumer market for genetic testing. Having thus amassed a treasure trove of data, the company also uses the data to develop new pharmaceutical products and gene-based therapies. The firm has bristled at complying with US Food and Drug Administration regulations and faced scientific scrutiny, and yet the company is carving out a stubborn success story. Science journalist Erika Check Hayden illuminates the origins, tribulations and ambitious goals of 23andMe and paints a lively portrait of the company’s determined leader. getAbstract recommends this article to anyone interested in pharmaceutical innovations, to the health care sector and to those with a fondness for start-up stories with gutsy protagonists.
In this summary, you will learn
- How the market of direct-to-consumer genetic testing developed,
- How researchers use 23andMe’s data for drug development and
- Why the US Food and Drug Administration temporarily barred 23andMe from selling testing kits.
About the Author
Erika Check Hayden is a science journalist in San Francisco, California.